Menarini Looks East With Invida Acquisition

Italy's Menarini has hit the acquisition trail and bought Invida of Singapore, having chosen the Asia-Pacific region as a key area for growth. Invida was formed in 2005 by Temasek Holdings, Quintiles and Zuellig. The groups are selling a firm which has turnover of around 160 million, 3,500 employees "and a consolidated presence in a number of extremely important therapeutic areas". Financial details have not been disclosed. Menarini sees Indiva as "the ideal company to serve as a gateway for many significant emerging countries. Specifically, it is looking at Australia, China, Hong Kong, India, Indonesia, Malaysia, New Zealand, South Korea, Taiwan, Thailand, the Philippines, and Vietnam, as well as Singapore. Invida is particularly active in dermatology, primary care, consumer health and specialty treatments. It has partnerships in place with many of the world's major drugmakers, including Pfizer, Sanofi, GlaxoSmithKline and Novartis, and sells over 70 brands in 13 markets. Chief executive Alberto Giovanni Aleotti said that "we have been committed to the acquisition of Invida for some time”, adding that "we look forward to gaining first-hand experience of the great vitality of this region". The latter "is a place where one can find a strong concentration of highly skilled professionals and companies, thanks to the Singaporean government’s policies that support business growth and innovation,” he concluded.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!